Estrogen receptor β in Alzheimer’s disease: From mechanisms to therapeutics
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) disproportionally affects women and men. The female susceptibility for AD has been largely associated with the loss of ovarian sex hormones during menopause. This review examines current understanding of the role of estrogen receptor β (ERβ) in the regulation of neurological health and its implication in the development and intervention of AD. Since its discovery in 1996, research conducted over the last 15-20 years has documented a great deal of evidence indicating that ERβ plays a pivotal role in a broad spectrum of brain activities from development to aging. ERβ genetic polymorphisms have been associated with cognitive impairment and increased risk for AD predominantly in women. The role of ERβ in the intervention of AD has been demonstrated by the alteration of AD pathology in response to treatment with ERβ-selective modulators in transgenic models that display pronounced plaque and tangle histopathological presentations as well as learning and memory deficits. Future studies that explore the potential interactions between ERβ signaling and the genetic isoforms of human apolipoprotein E (APOE) in brain aging and development of AD-risk phenotype are critically needed. The current trend of lost-in-translation in AD drug development that has primarily been based on early-onset familial AD (FAD) models underscores the urgent need for novel models that recapitulate the etiology of late-onset sporadic AD (SAD), the most common form of AD representing more than 95% of the current human AD population. Combining the use of FAD-related models that generally have excellent face validity with SAD-related models that hold more reliable construct validity would together increase the predictive validity of preclinical findings for successful translation into humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“…(hAPPK670N,M671L) (Hsiao et al., 1996), J9 (hAPPK670N,M671L,V717F) (Hsia et al., 1999), 5xFAD (hAPPK670N,M671L,I716V,V717I + hPS1M146L,L286V) (Oakley et al., 2006), 3xTg-AD (hAPPK670N,M671L + hPS1M146V + hTau P301L) (Oddo et al., 2003), and the recently developed human neural stem cell…”
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 2×
“APOE2 is relatively rare, with only 5% incidence, and it is recognized as a protective variant against AD (Kim et al., 2009; Liu et al., 2013).”
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 2×
“To date, several dozen AD models that mimic the genetic cause of AD have been developed, including the widely used models such as PDAPP (hAPP) (Games et al., 1995), Tg2576 (hAPP) (Hsiao et al.”
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 2×
“APOE2 is relatively rare, with only 5% incidence, and it is recognized as a protective variant against AD (Kim et al., 2009; Liu et al., 2013).”
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · cited 3×
“, 2003), and the recently developed human neural stem cell derived three-dimensional culture system ((hAPP, PS1-dE9) (Choi et al., 2014).”
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123 · cited 2×
“, 1996), J9 (hAPP) (Hsia et al., 1999), 5xFAD (hAPP + hPS1) (Oakley et al.”
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 1×
“The age difference between sexes appears to be even smaller in rodents; in C57BL/6 mice, female mean life span was 789 ± 42 days, and male was 801 ± 39 days (Selman et al., 2009).”
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
BDNF and Activity-Dependent Synaptic Modulation: Figure 1.
Lu, B. (2003) · Learning & Memory · doi:10.1101/lm.54603 · Cited by 945
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940 · cited 2×
“development of AD, we recently conducted a pilot study designed to elucidate sex differences in hippocampal aging as demonstrated by the expression profile of a focused set of approximately 180 genes involved in mitochondrial bioenergetics and amyloid metabolism in light of their accentuated roles in preclinical devel…”
Self-citationEstrogen Actions Throughout the Brain
McEwen, B. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.357 · Cited by 915
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891 · cited 3×
“, 1998), a significant interaction between APOE2 and sex was also revealed in recent clinical studies in which a protective role of APOE2 was detected in male but not female subjects (Altmann et al., 2014; Ungar et al., 2014) .”
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874 · cited 2×
“As a prototypic neurotrophin, BDNF is structurally related to nerve growth factor but appears to have a greater expression and wider distribution in the CNS, with the greatest concentration found in the hippocampal formation (Murer et al., 2001).”
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · cited 2×
“development of AD, we recently conducted a pilot study designed to elucidate sex differences in hippocampal aging as demonstrated by the expression profile of a focused set of approximately 180 genes involved in mitochondrial bioenergetics and amyloid metabolism in light of their accentuated roles in preclinical devel…”
Postsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and disease
Yoshii, A., & Constantine‐Paton, M. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20765 · Cited by 744
Sex Differences in the Clinical Manifestations of Alzheimer Disease Pathology
Barnes, L. L., Wilson, R. S., Bienias, J. L., Schneider, J. A., Evans, D. A., & Bennett, D. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.685 · Cited by 643
Estrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000) · Neurology · doi:10.1212/wnl.54.10.1949 · Cited by 371 · cited 2×
“Consistent with the findings in animal models, a study conducted in 2,716 elderly women found that ET use was associated with less cognitive decline in APOE4-negative but not APOE4-positive individuals (Yaffe et al., 2000).”
Ward, A., Crean, S., Mercaldi, C. J., Collins, J. M., Boyd, D., Cook, M. N., & Arrighi, H. M. (2012) · Neuroepidemiology · doi:10.1159/000334607 · Cited by 349
Greater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis
Irvine, K., Laws, K. R., Gale, T. M., & Kondel, T. K. (2012) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2012.712676 · Cited by 290
Risk profiles for mild cognitive impairment and progression to dementia are gender specific
Artero, S., Ancelin, M.-L., Portet, F., Dupuy, A., Berr, C., Dartigues, J.-F., Tzourio, C., Rouaud, O., Poncet, M., Pasquier, F., et al. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.136903 · Cited by 281 · cited 1×
“For instance, depression is associated with a 2-fold increased risk for AD in women but not in men; whereas, stroke is associated with a 3-fold increased risk for AD in men but not in women; (Artero et al., 2008).”
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246 · cited 3×
“, 1998), a significant interaction between APOE2 and sex was also revealed in recent clinical studies in which a protective role of APOE2 was detected in male but not female subjects (Altmann et al., 2014; Ungar et al., 2014) .”
Sex and Gender Differences in Alzheimer's Disease: Recommendations for Future Research
Carter, C. L., Resnick, E. M., Mallampalli, M., & Kalbarczyk, A. (2012) · Journal of Women's Health · doi:10.1089/jwh.2012.3789 · Cited by 231 · cited 2×
“AD disproportionally affects women and men (Carter et al., 2012; Regitz-Zagrosek and Seeland, 2012).”
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · cited 1×
“However, men with one APOE4 allele had little to no bump in risk (Farrer et al., 1997).”
Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., & Burns, J. M. (2011) · Neurology · doi:10.1212/wnl.0b013e31820e7b74 · Cited by 99 · cited 2×
“…with a maternal family history of AD were found to express greater phenotypic changes in AD-vulnerable brain regions suggesting a higher risk for developing AD as compared to those with a paternal history or no family history (Berti et al., 2011; Honea et al., 2011; Mosconi et al., 2010).”
Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline
Kang, J. H., & Grodstein, F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.007 · Cited by 90 · cited 2×
“in the Nurses’ Health Study in which ET was associated with a worse rate of cognitive decline among APOE4 carriers (Kang and Grodstein, 2012).”
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes
Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-3-170 · Cited by 85 · cited 2×
“…with a maternal family history of AD were found to express greater phenotypic changes in AD-vulnerable brain regions suggesting a higher risk for developing AD as compared to those with a paternal history or no family history (Berti et al., 2011; Honea et al., 2011; Mosconi et al., 2010).”
Structural brain changes in normal individuals with a maternal history of Alzheimer's
Berti, V., Mosconi, L., Glodzik, L., Li, Y., Murray, J., De Santi, S., Pupi, A., Tsui, W., & De Leon, M. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.001 · Cited by 58
Chang, Y., Fennema‐Notestine, C., Holland, D., McEvoy, L. K., Stricker, N. H., Salmon, D. P., Dale, A. M., Bondi, M. W., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1763 · Cited by 39
Estrogen Receptor β Variants Modify Risk for Alzheimer's Disease in a Multiethnic Female Cohort
Janicki, S. C., Park, N., Cheng, R., Lee, J. H., Schupf, N., & Clark, L. N. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-130551 · Cited by 36
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Role of estrogen receptors in health and disease
Chen, P., Li, B., & Ou-Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839005 · Cited by 339
Uddin, M. S., Rahman, M. M., Jakaria, M., Rahman, M. S., Hossain, M. S., Islam, A., Ahmed, M., Mathew, B., Omar, U. M., Barreto, G. E., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01911-8 · Cited by 156
Yang, J., Zhi, W., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29122812 · Cited by 63
“It has been found that the oestrogen receptor (oestrogen receptor, ESR) has an important influence on the development of AD in women with the ApoE ε 4 genotype and that the oestrogen receptor and ApoE ε 4 interact with each other [132–134].”
Background
Metadata
- Authors
- Zhao, L., Woody, S. K., & Chhibber, A.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 24
- Issue
- Pt B
- Pages
- 178-190
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W1147961199
- Cited by
- 98
- References
- 36
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.